Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
This is a first-in-human study. The main goal of this study is to assess the safety and tolerability of mRNA-4359 given alone and in combination with pembrolizumab.
Why this Research Matters
The main purpose of this study is to test how safe these drugs are, and how well the body deals with effects of mRNA-4359 when it is given alone or in combination with pembrolizumab. The goal is to find a safe and acceptable dose in people with locally adv
Who can Participate
Adult
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. ClinicalTrials.gov to learn more about this study.
Study ID
Protocol Number: 22-1490
More information available at ClinicalTrials.gov: NCT05533697
Meet the Team
Principal Investigator